All In Biotech

Drug Trial Radar · NCT02658929

Study of bb2121 in Multiple Myeloma

CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Jan 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

67

Actual

Start

Dec 22, 2015

Primary completion

Jul 22, 2019

Study completion Sep 22, 2022

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Genetix Biotherapeutics Inc.
First posted
Jan 20, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM).

Conditions

  • Multiple Myeloma

Interventions

  • bb2121Biological

    bb2121

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs) and abnormal laboratory test results, including dose limiting toxicities (DLTs)Time frame: Day 1 through Month 60

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford Cancer Center

    Stanford, California

  • National Cancer Institute

    Bethesda, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Mt. Sinai Medical Center Division of Hematology/Oncology

    New York, New York

  • Sarah Cannon Research Inst

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.